teva_canada_1

Teva’s Ajovy injection secures EU approval for the prevention of migraine

April 2, 2019
Manufacturing and Production, Sales and Marketing EU, Europe, Teva, ajovy, migraine, pharma

Teva has announced that its calcitonin gene-related peptide (CGRP) inhibitor Ajovy (fremanezumab) has been awarded marketing authorisation by the European …

merckwindow_web

China approves Keytruda for non-small cell lung cancer

April 2, 2019
Manufacturing and Production China, MSD, Merck and Co, USA, keytruda, lung cancer, pharma

US firm MSD has won approval for Keytruda in China. The cancer immunotherapy has thus become the first PD-1 inhibitor …

Novartis must face kickback allegations in court

April 2, 2019
Manufacturing and Production Novartis, US, government, kickbacks, prescriptions, whistle blower, whistle-blower

The US government has accused Novartis of paying doctors millions of dollars in kickbacks as part of a “company-wide kickback …

ian-headshot

Artios Pharma name experienced oncologist as company’s new CMO

April 1, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Artios Pharma, CMO, Cancer, DDR, oncology

British biotech Artios Pharma have appointed experienced oncologist Dr Ian Smith, as the company’s new Chief Medical Officer (CMO). Dr …

love-and-drugs-1

How I learned to stop worrying and love the placebo effect

April 1, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing clinical trials, feature, pharma, placebo effect

Louis Goss talks to Harvard Medical School placebo expert Dr Ted Kaptchuk in asking what the placebo effect means for …

credit_-_daniel_leal-olivas-afp

CHMP recommendation for bluebird bio’s gene therapy in β-thalassaemia

April 1, 2019
Research and Development, Sales and Marketing Bluebird Bio, CHMP, EMA, Zynteglo, gene therapy, β-thalassaemia

Massachusetts-based bluebird bio has taken a significant leap forward in its pursuit of regulatory authorisation for its first gene therapy, …

Indian authorities say J&J’s baby shampoo contains ‘harmful ingredients’

April 1, 2019
Sales and Marketing Cancer, India, J&J, JJ, Johnson & Johnson, Rajasthan, baby shampoo, formaldehyde

Indian authorities in the state of Rajasthan have said that samples taken from Johnson & Johnson’s baby shampoo contained ‘harmful …

novartis_outside_1

Novartis inks $1.6 billion deal with immunology biotech IFM Therapeutics

April 1, 2019
Sales and Marketing Atlas Venture, Boston, IFM Therapeutics, Novartis, pharma

Swiss firm Novartis has agreed to pay a sum of $310 million upfront to Boston inflammation specialist IFM Therapeutics, as …

roche__tree

Roche’s Tecentriq combo shows promise in first-line triple-negative breast cancer

April 1, 2019
Research and Development, Sales and Marketing Cancer, Roche, breast cancer, pharma, tecentriq

Roche has revealed new Phase 1b data on a new Tecentriq combo, showing early promise in the first-line treatment of …

Lyrica to be made class C drug in Northern Ireland

April 1, 2019
Sales and Marketing Lyrica, Northern Ireland, class c, illegal drugs, pain, pregabalin

Pregabalin – sold under the brand name Lyrica – will now be treated as a class C drug in Northern …

shutterstock_273326141

AstraZeneca and Daiichi Sankyo partner up for $6.9 billion cancer collaboration

March 29, 2019
Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Cancer, Daiichi Sankyo, pharma

AstraZeneca and Daiichi Sankyo have announced a new collaboration agreement to the tune of potentially $6.9 billion which will see …

top_10_image

Top Ten most popular articles on Pharmafile.com this week!

March 29, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

A Japanese journalist was ordered to pay Â¥3.3 million to an anti-vaccine researcher, this week, after a court found her …

shutterstock_57369385

England’s antidepressant prescriptions double to 70m in a decade

March 29, 2019
Medical Communications England, UK, antidepressants, anxiety, depression, pharma

Figures released by NHS Digital have revealed that prescriptions for antidepressants in the UK have risen to 70.9 million, almost …

28246711066_52e38bc591_z

ABPI calls for temporary export ban in effort to prevent shortages in case of no-deal Brexit

March 29, 2019
Medical Communications ABPI, UK, brexit, drug shortages, export market

The Association of the British Pharmaceutical Industry (ABPI) has called for a temporary ban on exports as a means of …

920x920

Sacklers fraudulently transferred funds to dodge litigation, lawsuit says

March 29, 2019
Medical Communications Litigation, New York, OxyContin, Purdue Pharma, Sackelr, opioids

New York state prosecutors have filed a lawsuit against members of the Sackler family, alleging the Purdue Pharma controllers fraudulently …

vertex-headquarters

Vertex destroyed nearly 8,000 packs of Orkambi in 2018

March 28, 2019
Medical Communications, Sales and Marketing Briatin, Orkambi, UK, Vertex, cystic fibrosis

Vertex destroyed nearly 8,000 packs of the $272,000 a year cystic fibrosis drug Orkambi in 2018, the company said in …

eye2

J&J’s antihistamine-releasing contact lens shows promise in Phase 3 trials

March 28, 2019
Research and Development J&J, JJ, eye care, pharma

Johnson and Johnson has unveiled new Phase 3 data on its antihistamine-releasing contact lens, showing that the investigational product led …

AMR advisor calls for public utility company to tackle AMR

March 28, 2019
Medical Communications, Research and Development AMR, Lord Jim O'Neill, antimicrobial resistance, pharma, public health

Lord Jim O’Neill, an economist and former government advisor on antimicrobial resistance (AMR), has accused the pharmaceutical industry of “spewing …

AstraZeneca’s Imfinzi to be made available via Cancer Drugs Fund in England

March 28, 2019
Sales and Marketing AstraZeneca, Cancer, Imfinzi, NHS, NICE, UK, lung cancer

AstraZeneca’s PD-L1 inhibitor Imfinzi (durvalumab) will now be made available to English lung cancer patients on the NHS via the …

The Gateway to Local Adoption Series

Latest content